Recent Updates
Recently added Catalysts

Albuterol DPI/inh

Phase 2

Asthma | Small molecule | Respiratory |Amphastar Pharmaceuticals, Inc.|Last Updated: May 19, 2017

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment23

FDA Designations

No designations recorded

Clinical trial landscape

Albuterol DPI/inh · 1 trial · 1 indication

Phase 2 1
NCT01581177Albuterol DPI (A006) Clinical Study-B2: Efficacy, Dose-Ranging and Initial Safety EvaluationAsthma
COMPLETED23 Analytics
PHASE2COMPLETED
Albuterol DPI (A006) Clinical Study-B2: Efficacy, Dose-Ranging and Initial Safety Evaluation
AsthmaUnlock trial analytics

Study Endpoints

Primary Endpoints

Change in FEV1 Area Under the Curve (AUC) versus placebo
Visits 1-7, at baseline, 5, 20, 30, 60, 90, 120, 240, 360 minutes post-dose

Serial FEV1 measurements to demonstrate the mean AUC change in percent FEV1 from same-day baseline of A006 versus placebo control

Secondary Endpoints

Placebo AUC of adjusted FEV1 changes
Visits 1-7 at baseline, 5, 20, 30, 60, 90, 120, 180, 240 and 360 minutes post-dose
AUC of post-dose FEV1 volume changes from pre-dose baseline to Visit 7
Visits 1-7 at baseline, 5, 20, 30, 60, 90, 120, 180, 240, 360 minutes post-dose
Time post-dose change in FEV1 percent first reaches greater than or equal to 12 percent over the Pre-dose Baseline
Visits 1-7, at 5, 20, 30, 60, 90, 120, 180, 240 and 360 minutes post-dose
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingTRIPLE
ModelCROSSOVER
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
T1EXPERIMENTALTwo inhalations, one of Albuterol DPI 25 mcg/inh and one of Placebo DPI; Total Albuterol dose of 25 mcg
T2EXPERIMENTALTwo inhalations of Albuterol DPI 25 mcg/inh; Total Albuterol dose of 50 mcg
T3EXPERIMENTALTwo inhalations, one of Albuterol DPI 90 mcg/inh and one of Placebo DPI; Total Albuterol dose of 90 mcg
T4EXPERIMENTALTwo inhalations of Albuterol DPI 90 mcg/inh; Total Albuterol dose of 180 mcg
PPLACEBO_COMPARATORTwo inhalations Placebo DPI; Total Albuterol dose of 0 mcg
R1ACTIVE_COMPARATOROne inhalation of Albuterol MDI 90 mcg/inh; Total Albuterol dose of 90 mcg
R2ACTIVE_COMPARATORTwo inhalations of Albuterol MDI 90 mcg/inh; Total Albuterol dose of 180 mcg

Interventions

NameTypeDescription
Albuterol DPI 25 mcg/inhDRUGAlbuterol DPI with 25 mcg Albuterol/inhalation
Albuterol DPI 90 mcg/inhDRUGAlbuterol DPI with 90 mcg Albuterol/inhalation
Placebo DPIDRUGPlacebo DPI with 0 mcg Albuterol/inhalation
Albuterol MDI 90 mcg/inhDRUGAlbuterol MDI with 90 mcg Albtuerol/inhalation
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 55 Years
SexALL
Healthy VolunteersNo
Study Sites4

Inclusion Criteria: * Generally healthy, male and female adults, 18-55 years of age at screening * With mild-to-moderate persistent asthma for at least 6 months prior to screening and having used a beta-agonist(s) inhaler * Demonstrate a Forced Expiratory Volume (FEV1) at 50-85 percent of predicted...

Countries:United States
Unlock Eligibility Criteria